^
    Back
    Association details:
    Biomarker:EGFR L747P
    Cancer:Lung Adenocarcinoma
    Drug:gefitinib (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Lung Cancer
    Title:

    A rare EGFR mutation L747P conferred therapeutic efficacy to both gefitinib and osimertinib: A case report

    Published date:
    09/25/2020
    Excerpt:
    ...we reported a patient with advanced lung adenocarcinoma harboring an EGFR L747 P who benefited from first-line treatment with gefitinib. This patient achieved stable disease (SD) and had a progression-free survival (PFS) of 18 months.
    DOI:
    10.1016/j.lungcan.2020.09.017
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    J Thorac Oncol
    Title:

    A Novel EGFR Mutation in Exon 19 Showed Stable Disease After TKI Treatment

    Excerpt:
    We observed stable disease upon EGFR-TKI treatment in a patient with an adenocarcinoma of the lung that harbored a p.747P double-point mutation in exon 19.
    DOI:
    10.1097/JTO.0b013e31825ccae8